# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price targ...
Oppenheimer analyst Leland Gershell reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target f...
Goldman Sachs analyst Paul Choi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $180 to ...
BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by l...
Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia.
Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $170 price target.